Global Bioenergies (Euronext Growth: ALGBE) reaches 87% of yield target in Isobutene process
Global Bioenergies reaches 87% of yield target in Isobutene process
Evry, France - October 8, 2018 (Investorideas.com Newswire) Global Bioenergies (Euronext Growth: ALGBE) announces today that a new milestone has been met in the development of its Isobutene process. The company announces a yield exceeding 87% of the final target during the complete production phase, at laboratory scale. The productivity is also progressing quickly. Yield and productivity have reached a threshold meeting the expectations for profitable exploitation of the process at commercial scale for high value applications such as cosmetics.
Isobutene has a very broad range of applications, ranging from fuels and commodity chemicals to cosmetics. Global Bioenergies' goal is to provide a bio-based isobutene process meeting the requirements for all the applications, i.e. able to compete pricewise with fuels and materials derived from oil. The higher the performances, the lower the production costs, and thus the broader the range of applications that can be exploited profitably. Since more than 70% of the costs at commercial scale will be represented by the feedstock (the industrial grade sugar that is converted into isobutene), the most important parameter is yield.
In order to reach this milestone, Global Bioenergies has built new bacterial strains, with an entirely redesigned carbon metabolism. When provided with a powerful isobutene route, the improved strains have shown their capability, at lab scale, of achieving more than 87% of the final target yield over the whole production phase, meaning that 87% of the sugar consumed by the strains is directly contributing to produce isobutene.
In addition, the new strains show a markedly better productivity. Productivity speaks about the speed at which strains convert sugars into isobutene, and translates into OPEX and CAPEX cost, which will represent the remaining 30% of the costs at commercial scale.
Reproduced at commercial plant scale, these performances would sustain profitable exploitation for the high-value applications of isobutene, such as cosmetics. The process based on the new strains is presently moving down the scale-up chain, with first industrial pilot testing showing very promising results.
Frédéric Pâques, COO of Global Bioenergies declares: "The increase in performances we are observing over 2018 has contributed to considerably de-risk the project. We will continue to work at improving yield and productivity, but we have passed a threshold that allows us to balance the priorities. Our major objective is now to obtain a perfect stability in industrial conditions at demo scale. Given the current state of the art and the steep progression observed this last year, we should now reach new summits within months.".
Marc Delcourt, CEO of Global Bioenergies, adds: These outstanding progresses bode well for IBN-One, the first commercial plant project we co-own together with Cristal Union, one of the leaders in the European sugar industry. Our process will count in the technological arsenal our civilization now needs to win the battles against global warming, air pollution in cities, and oil depletion.
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performance of its process, to operate its demo plant in Germany, and to prepare the first full-scale plant through a joint venture with Cristal Union, named IBN-One. Global Bioenergies is listed on Euronext Growth Paris (FR0011052257 - ALGBE)
Stay informed! Subscribe to our newsfeed on www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Tel: +33 1 64 98 20 50
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release on the Investorideas.com newswire https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.